First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

doi:10.3748/wjg.v19.i28.4511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 28

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6021)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

380

HTML

3389

Figures (1-3)

137

Tables (1-4)

110

Sum=4016

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1122

Download

883

Sum=2005

Jul 28, 2013 (publication date) through May 1, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jul 28, 2013; 19(28): 4511-4519
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4511

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier analysis of progression-free survival and overall survival in the intent to treat population. A: Progression-free survival (PFS); B: Overall survival (OS).

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier analysis of independent progression-free survival predictors. A: Progression-free survival (PFS) by sex; B: PFS by skin rash; C: PFS by carbohydrate antigen 19-9 decrease.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan-Meier analysis of independent overall survival predictors. A: Overall survival (OS) by sex; B: OS by skin rash; C: OS by carbohydrate antigen 19-9 decrease; D: OS by Eastern Cooperative Oncology Group performance status (PS); E: OS by clinical benefit. Pos: Positive; Neg: Negative.

Citation: Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519
URL: https://www.wjgnet.com/1007-9327/full/v19/i28/4511.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i28.4511